Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vlatko Pejsa

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Lijecnicki Vjesnik|August 27, 2014
[The use of peripherally inserted central catheter (PICC) in patients with hematological malignancies--a single center experience]Zdravko Mitrović, Igor Komljenović, Ozren Jaksic, et al.
Acta Haematologica|May 19, 2016
The Degree of Anisocytosis Predicts Survival in Patients with Primary MyelofibrosisMarko Lucijanic, Vlatko Pejsa, Ozren Jaksic, et al.
International Journal of Hematology|October 13, 2017
Increased mean platelet volume (MPV) is an independent predictor of inferior survival in patients with primary and secondary myelofibrosisMarko Lucijanic, Zdravko Mitrovic, David Cicic, et al.
Leukemia & Lymphoma|December 18, 2019
Prolonged methylprednisolone premedication prior to obinutuzumab in patients with chronic lymphocytic leukemiaVlatko Pejsa, Marko Lucijanic, Anamarija Vrkljan Vuk, et al.
European Journal of Haematology|March 21, 2023
Dose-adjusted EPOCH and rituximab (DA-EPOCH-R) in older patients with high-risk aggressive diffuse large B-cell lymphoma: A real-life multicenter study by the Croatian Cooperative Group for Hematologic diseases (KroHem)Zdravko Mitrovic, Dino Dujmovic, Ozren Jaksic, et al.
Hematology (Amsterdam, Netherlands)|September 15, 2017
High absolute basophil count is a powerful independent predictor of inferior overall survival in patients with primary myelofibrosisMarko Lucijanic, Ana Livun, Tajana Stoos-Veic, et al.
Wiener Klinische Wochenschrift|January 27, 2018
Assessing serum albumin concentration, lymphocyte count and prognostic nutritional index might improve prognostication in patients with myelofibrosisMarko Lucijanic, Ivo Veletic, Dario Rahelic, et al.
Hemasphere|November 21, 2022
Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic DiseasesDavor Galusic, Sandra Basic-Kinda, Andela Pijuk, et al.
Blood Cancer Journal|April 21, 2022
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemiaKeith W Pratz, Panayiotis Panayiotidis, Christian Recher, et al.
The New England Journal of Medicine|August 14, 2020
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaCourtney D DiNardo, Brian A Jonas, Vinod Pullarkat, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Lijecnicki Vjesnik|August 27, 2014
[The use of peripherally inserted central catheter (PICC) in patients with hematological malignancies--a single center experience]Zdravko Mitrović, Igor Komljenović, Ozren Jaksic, et al.
Acta Haematologica|May 19, 2016
The Degree of Anisocytosis Predicts Survival in Patients with Primary MyelofibrosisMarko Lucijanic, Vlatko Pejsa, Ozren Jaksic, et al.
International Journal of Hematology|October 13, 2017
Increased mean platelet volume (MPV) is an independent predictor of inferior survival in patients with primary and secondary myelofibrosisMarko Lucijanic, Zdravko Mitrovic, David Cicic, et al.
Leukemia & Lymphoma|December 18, 2019
Prolonged methylprednisolone premedication prior to obinutuzumab in patients with chronic lymphocytic leukemiaVlatko Pejsa, Marko Lucijanic, Anamarija Vrkljan Vuk, et al.
European Journal of Haematology|March 21, 2023
Dose-adjusted EPOCH and rituximab (DA-EPOCH-R) in older patients with high-risk aggressive diffuse large B-cell lymphoma: A real-life multicenter study by the Croatian Cooperative Group for Hematologic diseases (KroHem)Zdravko Mitrovic, Dino Dujmovic, Ozren Jaksic, et al.
Hematology (Amsterdam, Netherlands)|September 15, 2017
High absolute basophil count is a powerful independent predictor of inferior overall survival in patients with primary myelofibrosisMarko Lucijanic, Ana Livun, Tajana Stoos-Veic, et al.
Wiener Klinische Wochenschrift|January 27, 2018
Assessing serum albumin concentration, lymphocyte count and prognostic nutritional index might improve prognostication in patients with myelofibrosisMarko Lucijanic, Ivo Veletic, Dario Rahelic, et al.
Hemasphere|November 21, 2022
Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic DiseasesDavor Galusic, Sandra Basic-Kinda, Andela Pijuk, et al.
Blood Cancer Journal|April 21, 2022
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemiaKeith W Pratz, Panayiotis Panayiotidis, Christian Recher, et al.
The New England Journal of Medicine|August 14, 2020
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaCourtney D DiNardo, Brian A Jonas, Vinod Pullarkat, et al.
Pageof 4